Topic: Miscellaneous

SEC Provides New Option for Extending Confidential Treatment
NYSE's Attempt to Allow Primary Offerings in Direct Listings Hits a Snag
SEC Reduces Filing Fee Rate Effective October 1, 2020
SEC Issues Guidance Regarding Submission of Supplemental Materials and Confidential Treatment Requests in Light of COVID-19 Concerns
SEC Staff provides additional disclosure guidance related to COVID-19 impact
Key Considerations for Issuers and Auditors Regarding Going-Concern Analysis
Nasdaq Provides Temporary Exemption from Certain Shareholder Approval Requirements in Response to COVID-19
SEC Releases COVID-19 FAQs to Provide Guidance on Disclosure Requirements and Form S-3
Now Available: COVID-19 Resources for Public Companies
NYSE and Nasdaq Propose Temporary Waivers of Certain Market Capitalization and Trading Price Listing Requirements
1 - 10 Next

 Error

Web Part Error: A Web Part or Web Form Control on this Page cannot be displayed or imported. The type could not be found or it is not registered as safe. Correlation ID: 14ae7c9f-89be-c0be-1461-c6a394c2f4dd.

© Copyright 2018 Gibson, Dunn & Crutcher LLP.
Attorney Advertising. Prior results do not guarantee a similar outcome. All information provided on this site is for informational purposes only, does not constitute legal advice, is not confidential, and does not create an attorney-client relationship. Statements and content posted to this site do not represent the opinion of Gibson Dunn & Crutcher LLP ("Gibson Dunn"). Gibson Dunn makes no representations as to the accuracy, completeness, currentness, suitability, or validity of any information on this site and will not be liable for any errors or omissions therein, nor for any losses, injuries, or damages arising from its display or use.